Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 4.34B | 4.37B | 4.50B | 4.58B | 4.53B | 3.24B |
Gross Profit | 2.88B | 2.86B | 2.74B | 2.97B | 3.15B | 2.20B |
EBITDA | -465.00M | -725.00M | -608.00M | -3.92B | 747.00M | 767.00M |
Net Income | -965.00M | -1.22B | -1.16B | -4.40B | 762.00M | 656.00M |
Balance Sheet | ||||||
Total Assets | 6.18B | 6.30B | 10.11B | 12.25B | 15.22B | 7.58B |
Cash, Cash Equivalents and Short-Term Investments | 1.24B | 1.22B | 1.05B | 2.04B | 1.34B | 3.47B |
Total Debt | 2.61B | 2.62B | 2.26B | 3.48B | 2.47B | 1.85B |
Total Liabilities | 3.81B | 3.93B | 4.37B | 5.65B | 4.48B | 2.89B |
Stockholders Equity | 2.37B | 2.37B | 5.75B | 6.60B | 10.74B | 4.69B |
Cash Flow | ||||||
Free Cash Flow | 869.00M | 709.00M | 282.00M | -74.00M | 337.00M | 891.00M |
Operating Cash Flow | 1.00B | 837.00M | 478.00M | 392.00M | 545.00M | 1.08B |
Investing Cash Flow | -193.00M | -178.00M | -231.00M | -591.00M | -1.07B | -554.00M |
Financing Cash Flow | -800.00M | -570.00M | -1.21B | 1.00B | -51.00M | -766.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | $43.65B | 50.15 | 59.33% | ― | 5.56% | 4.66% | |
79 Outperform | $34.22B | 29.71 | 18.88% | 0.82% | 0.56% | -4.08% | |
77 Outperform | $28.48B | 22.44 | 21.65% | ― | 2.84% | -0.16% | |
73 Outperform | $159.10B | 24.73 | 13.73% | 0.40% | 0.96% | 9.19% | |
72 Outperform | $144.92B | 39.26 | 7.22% | 0.63% | -9.19% | -12.75% | |
54 Neutral | $15.88B | ― | -23.82% | ― | -3.47% | 25.55% | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% |
On June 22, 2025, Illumina entered into a definitive agreement to acquire SomaLogic and other assets from Standard BioTools for $350 million in cash, with additional performance-based milestones and royalties. This acquisition aims to enhance Illumina’s presence in the expanding proteomics market and advance its multiomics strategy, building on a co-development partnership with SomaLogic since 2021. The transaction is expected to close in the first half of 2026, subject to regulatory approvals and customary conditions, and is anticipated to be profitable by 2027.
The most recent analyst rating on (ILMN) stock is a Buy with a $180.00 price target. To see the full list of analyst forecasts on Illumina stock, see the ILMN Stock Forecast page.
On May 21, 2025, Illumina, Inc. held its annual meeting of stockholders where several key proposals were approved. These included the election of eleven directors to the board, the ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 28, 2025, the approval of executive compensation, and the amendment of the 2015 Stock and Incentive Plan. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (ILMN) stock is a Buy with a $160.00 price target. To see the full list of analyst forecasts on Illumina stock, see the ILMN Stock Forecast page.